Notícias e Atividades da Journey Medical Corp

A Journey Medical Corp pertence à Fortress Biotech.

Fortress Biotech é uma empresa listada sob o símbolo FBIO (US).

Fortress Biotech possui 4 subsidiárias incluindo Avenue Therapeutics, Checkpoint Therapeutics e Journey Medical Corp.

Eles estão dentro:

• Biotecnologia80%
• Farmacêutica20%

Veja o organograma con seus 12 executivos principais

Biografias mais buscadas da Journey Medical Corp

• Claude Maraoui, Director, President and Chief Executive Officer
• Justin Smith, Director
• Michael Pearce, Director

Recentes movimentos de executivos em Fortress Biotech

• George Avgerinos, Senior Vice President, Biologics Operations, deixou a Companhia  (Notícia publicada em 28 de novembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Journey Medical Corp.

Fortress Biotech possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Corden Pharma has announced the acquisition of AmbioPharm  (publicado em 5 de junho de 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (publicado em 4 de junho de 2026).
• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott
• Jonathan Leff - Director da Larimar Therapeutics

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Journey Medical Corp

• Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
• Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
• Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
• Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
• Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
• Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
• Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
• Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
• Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
• Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
• View more press releases Close

Redes sociais sobre Journey Medical Corp

• Journey Medical Corp na Wikipedia, Google News e Yahoo Finance
• Journey Medical Corp na LinkedIn, X (Twitter) e YouTube